Bemarituzumab | Interleukin Related interleukin-related.com

Product Name :
Bemarituzumab

Search keywords :
Bemarituzumab

drugId :
null

Target Vo:
Fibroblast growth factor receptor 2

Target Vo Short Name :
FGFR2

Moa_Name:
Fibroblast growth factor receptor 2 antagonists

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Five Prime Therapeutics Inc

Active Company_Name :
Amgen Inc

Active Indication_Name:
Stomach Neoplasms

In Active Indication_Name:
Neoplasms

Termination Status :

China Termination Status :

Highest Status:
Phase 3 Clinical

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
PKC beta 2 Rabbit mAb Description
S100A4 Rabbit mAb Biological Activity
TAK1 Antibody (YA042): TAK1 Antibody (YA042) is a non-conjugated and Rabbit origined monoclonal antibody about 67 kDa, targeting to TAK1. It can be used for WB,ICC/IF,IHC-P,FC assays with tag free, in the background of Human, Mouse.

Author: Interleukin Related

Related Posts